Copyright ©The Author(s) 2020.
World J Hepatol. Aug 27, 2020; 12(8): 485-492
Published online Aug 27, 2020. doi: 10.4254/wjh.v12.i8.485
Table 1 Direct-acting antivirals approved for adolescents aged 12 to 17 years in Europe (May 2020)[20,22-24]
Direct-acting antivirals regimen (doses per d)Hepatitis C virus genotypePatientsDuration of treatment in wk
Sofosbuvir/ledipasvir (400/90 mg)1Treatment-naïve with or without cirrhosis or treatment-experienced without cirrhosis12
Treatment-experienced with cirrhosis24
4, 5, 6Treatment-naïve or treatment-experienced, with or without cirrhosis12
Sofosbuvir + ribavirin (400 mg + 15 mg/kg)2Treatment-naïve or treatment-experienced, with or without cirrhosis12
Glecaprevir/pibrentasvir (300/120 mg)All genotypesWithout cirrhosis8
All genotypesWith cirrhosis12
3Treatment experienced16
Table 2 Recommendations for the management of pediatric patients with chronic hepatitis C virus infection during the coronavirus disease 2019 pandemic[35,39]
Physical distancingRecommended
Patient education on risk and precaution on COVID-19Recommended
Testing for severe acute respiratory syndrome coronavirus infectionRecommended in patients with clinical symptoms suggesting COVID-19, or with household contact with an infected family member, or requiring hospitalization
Visits to specialized centersShould be postponed
Routine laboratory testingShould be performed (only if truly necessary) locally/offsite
Direct-acting antiviral therapy already initiatedShould be continued
Starting direct-acting antiviral treatmentMay be postponed in patients with stable chronic hepatitis C. If possible, it should be considered in patients with significant fibrosis or human immunodeficiency virus/hepatitis C virus coinfection
Telemedicine/visits by phoneRecommended instead of face-to-face visits whenever possible
Drug supplyHome delivery or sending prescriptions by e-mail
Liver-related diagnostic proceduresShould be deferred unless they are likely to change management